XLRN News and Press, Acceleron Pharma Inc. From 12/30/19

Acceleron Pharma ( XLRN -0.7% ) inks a collaboration and license agreement with Fulcrum Therapeutics ( FULC ) aimed at identifying small molecules designed to modulate specific pathways associated with an undisclosed pulmonary disease indication. More news on: Acceleron Pharma Inc., Fu...

Fulcrum to receive $10 million upfront payment and be eligible for future milestone payments Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, and Fulcrum Th...

The following slide deck was published by Acceleron Pharma Inc. in conjunction with this Read more ...

Initial results from phase 2 study evaluating an investigational use of luspatercept-aamt in myelofibrosis-associated anemia showed promising clinical activity – companies plan to initiate pivotal, phase 3 study called INDEPENDENCE in 2020 Longer-term follow-up from pivotal p...

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Jay T. Backstrom, M.D., M.P.H., as Executive Vice President, Research and Devel...

Bristol-Myers Squibb Company (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that following the late-cycle review meeting on December 4, 2019, they were notified by the U.S. Food and Drug Administration (FDA) that Reblozyl (luspatercept-aamt) will not be reviewed at t...

Noteworthy events during the week of December 8 - 14 for healthcare investors. More news on: Roche Holding AG, Athenex, Inc., Anixa Biosciences, Inc., Healthcare stocks news, , Read more ...

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Kemal Malik, MB BS, to its Board of Directors. Dr. Malik, who is currently a me...

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that it has been included in the recently released Institutional Investor 2020 “All-America...

The FDA's Oncologic Drugs Advisory Committee will meet  on Wednesday, December 18, to review and discuss Bristol-Myers Squibb's ( BMY -0.4% ) supplemental marketing application seeking approval to use Reblozyl (luspatercept-aamt) to treat patients myelodysplastic syndromes (MDS), spe...